MedTrace Logo

A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

NCT00035529 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2010-12-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo

Conditions

Interventions

DRUG

Placebo

Solution, i.v infusion, 0 mg, Days 1 \& 15 then monthly, 10 months.

DRUG

BMS 188667 (Abatacept)

Vial, i.v infusion, 2mg/kg, Days 1 \& 15 then monthly, 10 months.

DRUG

BMS 188667 (Abatacept)

Vial, i.v infusion, 10 mg/kg, Days 1 \& 15 then monthly, 10 months.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30
Primary Completion
2003-12-31
Completion
2003-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00035529 on ClinicalTrials.gov